An Exciting New Drug Is in Clinical Trials for Aspreva Pharmaceuticals
Richard Glickman was the CEO of Aspreva Pharmaceuticals, which put out CellCept, a drug that treats patient with lupus who develop kidney disease. Glickman has moved on to Aurinia Pharmaceuticals (NASDAQ: AUPH), and now is working on another drug, Voclosporin, for the same indication.
In this Industry Focus: Healthcare clip, Motley Fool analyst Kristine Harjes and contributor Todd Campbell explain what both drugs do, how far along in the FDA gauntlet Voclosporin is today, and why investors should be so excited to see whether or not it gets approved.
A full transcript follows the video.
Source: Fool.com
Aurinia Pharmaceuticals Inc. Aktie
6,28 €
-3,15 %
Noch kein Trend absehbar bei Aurinia Pharmaceuticals Inc. mit nur einigen Einschätzungen.
Trotz eines Kursziels von 10 €, das über 6.28 € liegt, ergibt sich für Aurinia Pharmaceuticals Inc. ein Potenzial von 59.29%.
